Altered S100 Calcium-Binding Protein B and Matrix Metallopeptidase 9 as Biomarkers of Mesial Temporal Lobe Epilepsy with Hippocampus Sclerosis

Meguid, Nagwa A.; Samir, Hatem; Bjørklund, Geir; Anwar, Mona; Hashish, Adel F.; Koura, Farouk; Chirumbolo, Salvatore; Hashem, Saher; El‐Bana, Mona A.; Hashem, Hebatalla S.

doi:10.1007/s12031-018-1164-5

Cited by 16 publications

(18 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Evaluating serum concentration of MMP-9 in pediatric and adult patients with mesial temporal lobe epilepsy (MTLE) revealed that MMP-9 levels in ES patients were increased compared to those in the control group. While a negative association was found between MMP-9 and the psychometric test, positive association was detected between severity of the seizure and MMP-9 . In line with these findings, the potential role of serum MMP-9 in adult patients with GCS has been shown recently…”

Section: Resultssupporting

confidence: 75%

“…While a negative association was found between MMP-9 and the psychometric test, positive association was detected between severity of the seizure and MMP-9. 22 In line with these findings, the potential role of serum MMP-9 in adult patients with GCS has been shown recently. 23 2.3.4.…”

Section: Ubiquitin Carboxyl-terminal Hydrolase L1 (Uchl-1)supporting

confidence: 61%

“…A remarkable correlation was observed between S100B levels and bilateral mesial temporal sclerosis but not between the lesion side and psychometric measurements. 22 It seems that serum level of S100B increases at a very early time point, as a study by Bai et al showed higher S100B concentration at 6 h after seizure attack in epileptic children, which then significantly decreased at 24 h, suggesting that brain damage recovers rapidly after ES attack and S100B protein degrades quickly in vivo particularly in the early phase of epilepsy. 34 Elevated S100B level has been also shown in ES group compared to PNES patients and healthy individuals.…”

Section: Ubiquitin Carboxyl-terminal Hydrolase L1 (Uchl-1)mentioning

confidence: 91%

See 2 more Smart Citations

Elevated Blood-Based Brain Biomarker Levels in Patients with Epileptic Seizures: A Systematic Review and Meta-analysis

Simani

Sadeghi

Ryan

et al. 2020

ACS Chem. Neurosci.

View full text Add to dashboard Cite

Recently, growing attention has been paid to the changes of brain biomarkers following the epilepsy. However, establishing specific epilepsy-related biomarkers has been impeded due to contradictory findings. This study systematically reviewed the evidence on brain biomarkers in epilepsy and determined reliable biomarkers in epileptic patients. A comprehensive systematic search of online databases was performed to find eligible studies up to August 2019. The quality of studies methodologically was assessed using the Newcastle–Ottawa Scale score. Among the several biomarkers, S100 calcium binding protein B (S100B) and neuron specific enolase (NSE) have been qualified for meta-analysis of the association between epilepsy and the brain biomarkers. Inverse-variance weights method was used to calculate pooled standardized mean difference (SMD) estimate with 95% CI, and random effects meta-analysis was conducted taking into account conceptual heterogeneity. Sensitivity analysis and publication bias assessment was performed using Stata. Of 29 studies that were qualified for further analysis, only 22 studies were eligible to quantify by meta-analysis. Significant increase of serum S100B levels (SMD = 0.80; 95% CI 0.18 to 1.42) but not NSE (SMD = 0.45; 95% CI −0.09 to 1.00) has been found in epileptic patients compared with healthy controls. Subgroup meta-analysis by age demonstrated that S100B could be found in pediatric (SMD = 1.15; 95% CI 0.03 to 2.27) not adult patients (SMD = 0.43; 95% CI −0.12 to 0.98). Findings of this meta-analysis indicate that serum level of S100B is significantly increased in epileptic patients, suggesting the elevation and release of the brain biomarkers from brain to blood following epileptic seizures.

show abstract

Section: Resultssupporting

confidence: 75%

Section: Ubiquitin Carboxyl-terminal Hydrolase L1 (Uchl-1)supporting

confidence: 61%

Section: Ubiquitin Carboxyl-terminal Hydrolase L1 (Uchl-1)mentioning

confidence: 91%

See 1 more Smart Citation

Elevated Blood-Based Brain Biomarker Levels in Patients with Epileptic Seizures: A Systematic Review and Meta-analysis

Simani

Sadeghi

Ryan

et al. 2020

ACS Chem. Neurosci.

View full text Add to dashboard Cite

show abstract

“…These biomarkers include the S100B protein, whose serum and plasma levels are measured after seizures to assess brain damage. Indeed, it was found that serum and plasma levels of S100B in both adults and children epileptic patients were significantly increased (Palmio et al, 2008;Kaciński et al, 2012;Calik et al, 2013Calik et al, , 2014Meguid et al, 2018;Zhu et al, 2018;Lu et al, 2010). Recent meta-analysis studies, that systematically analyzed all the available data about the presence of S100B in the serum of epileptic patients, confirmed the significant increase of S100B, indicating that epileptic seizures induce a boost and consequent release of brain biomarkers in the blood from the brain (Liang et al, 2019;Simani et al, 2020).…”

Section: Epilepsymentioning

confidence: 96%

Growing role of S100B protein as a putative therapeutic target for neurological- and nonneurological-disorders

Michetti

Sante

Clementi³

et al. 2021

Neuroscience & Biobehavioral Reviews

View full text Add to dashboard Cite

“…[3] S-100β and HMGB-1 protein are serum markers of cerebral injury which have been studied the most recently, and they have an important predictive value of the curative effect and prognosis for children epilepsy. [4,5] This research is intended to explore the efficacy of sodium valproate combined with levetiracetam in the treatment of children epilepsy and the influences on S-100β and HMGB-1, in order to provide a reference for the clinical treatment of children epilepsy. The research results are reported as follows.…”

Section: Introductionmentioning

confidence: 99%

Effects of sodium valproate combined with levetiracetam in treatment of children epilepsy and its influences on serum S-100 and high mobility group box-1

Hao

Chen

et al. 2020

DCC

View full text Add to dashboard Cite

Objective: To explore the effects of sodium valproate combined with levetiracetam in the treatment of children epilepsy, and its influences on serum S-100 and high mobility group box-1 (HMGB-1) in children with epilepsy.Methods: A total of 160 children who were diagnosed as epilepsy in Baogang Hospital of Inner Mongolia from July 2016 to October 2018 were selected as research objects. They were randomly divided into the study group (n = 80) and the control group (n = 80) by the random number table method, i.e., they were treated with sodium valproate combined with levetiracetam and sodium valproate alone, respectively. After 16 weeks of treatment, the effective rates of epileptic seizure treatment and the improvement of epileptiform discharge were evaluated, and chi-square test was used for statistical comparison. The related indicators, including serum tumor necrosis factor- (TNF-), hypersensitive C-reactive protein (hs-CRP), homocysteine (Hcy), haematocrit (HCT), erythrocyte sedimentation rate (ESR), serum S-100 and HMGB-1, were measured before and after treatment. Paired t-test was used for the comparison in the above indicators within a group before and after treatment; group t-test was used for the comparison between two groups. Chi-square test was used for the comparison in the rate of adverse reactions during treatment between two groups. The study was approved by Ethics Committee of Baogang Hospital (Approval No.: BG201606073), and all children’s guardians were required to sign informed consent forms for clinical study. There were no statistically significant differences between two groups in general clinical data (p > .05), such as sex constituent ratio, age, the course of disease, the frequency of epileptic seizure per year before treatment, the incidence of epileptiform discharge before treatment and the constituent ratio of types of epileptic seizure, etc.Results: 1) After treatment, the effective rates of epileptic seizure treatment and the improvement of epileptiform discharge in the study group were 92.5% (74/80) and 85.0% (68/80) respectively, which were both significantly higher than those in the control group [68.8% (55/80) and 58.8% (47/80)], and the differences were statistically significant (2 = 14.444, 13.635; p < .001). 2) In the study group, the levels of serum TNF-, hs-CRP and Hcy, as well as HCT and ESR after treatment were (53.1 ± 14.0) pg/ml, (5.0 ± 2.5) mg/L, (12.5 ± 3.1) μmol/L, (38.1 ± 5.1)% and (3.0 ± 0.5) mm/h respectively, which were all significantly lower than those [(107.9 ± 17.8) pg/ml, (10.1 ± 2.5) mg/L, (42.2 ± 5.8) μmol/L, (45.3 ± 4.5)% and (5.2 ± 0.6) mm/h] before treatment, and all the differences were statistically significant (t = 21.644, 12.902, 40.393, 9.468, 25.194; p < .001). In the control group, the levels of serum TNF-, hs-CRP and Hcy, as well as HCT and ESR after treatment were (60.6 ± 17.8) pg/ml, (8.2 ± 2.2) mg/L, (15.2 ± 3.1) μmol/L, (40.2 ± 3.4)% and (4.5 ± 0.6) mm/h respectively, which were all significantly lower than those [(112.4 ± 14.3) pg/ml, (9.3 ± 3.8) mg/L, (41.1 ± 2.8) μmol/L, (44.6 ± 5.5)% and (5.4 ± 0.8) mm/h] before treatment, and all the differences were statistically significant (t = 20.292, 2.241, 55.456, 3.320, 8.050; p < .05). After treatment, the above indicators in the study group were all significantly lower than those in the control group, and all the differences were statistically significant (t = 2.962, 8.595, 5.508, 3.064, 17.178; p < .05). 3) In the study group, the levels of serum S-100 and HMGB-1 after treatment were (0.65 ± 0.38) μg/L and (5.3 ± 2.4) μg/L respectively, which were significantly lower than those [(0.91 ± 0.32) μg/L and (8.1 ± 2.0) μg/L] before treatment, and the differences were statistically significant (t = 4.681, 8.020; p < .001). In the control group, the levels of serum S-100 and HMGB-1 after treatment were (0.78 ± 0.27) μg/L and (6.4 ± 2.2) μg/L respectively, which were significantly lower than those [(0.88 ± 0.25) μg/L and (7.9 ± 1.7) μg/L] before treatment, and the differences were statistically significant (t = 2.431, p = .016; t = 4.826, p < .001). After treatment, the levels of serum S-100 and HMGB-1 in the study group were significantly lower than those in the control group, and the differences were statistically significant (t = 2.495, p = .014; t = 2.840, p = .005). 4) There was no significant difference between two groups in the rate of adverse reactions, such as nausea, vomiting, poor appetite, dizziness, drowsiness, hepatic and renal injury during treatment (p > .05).Conclusions: The efficacy of sodium valproate combined with levetiracetam is obviously better than that of sodium valproate alone in the treatment of children epilepsy. The children patients’ serum S-100 and HMGB-1 are more significantly reduced, resulting in a lower rate of adverse reactions, which has a certain clinical value.

show abstract

Altered S100 Calcium-Binding Protein B and Matrix Metallopeptidase 9 as Biomarkers of Mesial Temporal Lobe Epilepsy with Hippocampus Sclerosis

Cited by 16 publications

References 50 publications

Elevated Blood-Based Brain Biomarker Levels in Patients with Epileptic Seizures: A Systematic Review and Meta-analysis

Elevated Blood-Based Brain Biomarker Levels in Patients with Epileptic Seizures: A Systematic Review and Meta-analysis

Growing role of S100B protein as a putative therapeutic target for neurological- and nonneurological-disorders

Effects of sodium valproate combined with levetiracetam in treatment of children epilepsy and its influences on serum S-100 and high mobility group box-1

Contact Info

Product

Resources

About